Type: stem_cell
Status: Ongoing Clinical Trials
Developer: Vertex Pharmaceuticals
Vertex's VX-880 therapy continues to show remarkable promise for Type 1 diabetes. In ongoing trials, multiple patients with severe hypoglycemia unawareness have achieved insulin independence after a single infusion of these stem cell-derived islets. It represents one of the most advanced and viable paths toward a functional cure currently in FDA-regulated trials.
VX-880 consists of fully differentiated, insulin-producing islet cells grown in a lab from allogeneic stem cells. Delivered via an infusion into the portal vein, these cells engraft in the liver and take over the job of the damaged pancreas, regulating blood sugar in response to meals just like a healthy organ.
Year: 2025